Page last updated: 2024-08-21

plumbagin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

plumbagin has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
McKallip, RJ; Sun, J	1

Other Studies

1 other study(ies) available for plumbagin and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Article	Year
Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leukemia research, 2011, Volume: 35, Issue:10 Topics: Acetylcysteine; Apoptosis; Blotting, Western; Catalase; Cell Survival; Flow Cytometry; Gene Expression; Humans; In Situ Nick-End Labeling; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Naphthoquinones; Oxidation-Reduction; Oxidative Stress; Polyethylene Glycols; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction	2011

Article

Year

Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression.

Leukemia research, 2011, Volume: 35, Issue:10

Topics: Acetylcysteine; Apoptosis; Blotting, Western; Catalase; Cell Survival; Flow Cytometry; Gene Expression; Humans; In Situ Nick-End Labeling; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Naphthoquinones; Oxidation-Reduction; Oxidative Stress; Polyethylene Glycols; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction

2011